Smith & Nephew PLC ORD USD0.20

 
SN. 
(LSE, Stocks) 

To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed.

p 580.99 <%= Resources.Global.txtUp %>
Updated 21/05/2012
ISIN: GB0009223206
Change % 0.2% Stock price increasing
Change 0.9903 Stock price increasing
Volume 1,214,996
High P 585.50
Low P 577.00
Open P 577.50
 
Prev close P 580.00
# of shares -
Market cap -
Intraday

Market closed
Smith & Nephew PLC ORD USD0.20
Market is closed, opens at 08:00
 
Price development Latest 1 week 1 month 3 mon 6 mon 1 year
 
  580.99 -2.3% Stock price decreasing -5.1% Stock price decreasing -7.6% Stock price decreasing 3.1% Stock price increasing -15.8% Stock price decreasing

Company profile

Smith & Nephew (S&N) is a global medical devices business which operates in Orthopaedics (55% of total sales), Endoscopy (22%) and Advanced Wound Management (AWM) (23%) with market share of 11%, 22% and 18% respectively. Growth in S&N’s markets is driven by demographic changes such as an ageing population, increasing obesity rates in mature economies. S&N believes that the estimated potential market in AWM is much larger and might be a strong growth factor for the company. Because of spiralling healthcare costs and government austerity measures, the industry is facing strong price pressures which is hurting growth. The new CEO is focussing on BRIC countries, innovation and possible acquisitions to bolster the company’s growth. The change in CEO should have a large impact on S&N, as the company has been focusing on conservative fiscal management and cautious emerging market growth. The low debt load should make the company’s growth strategy achievable.
Copyright Euroinvestor A/S 2012
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
Version: LiveBranchBuild_20120516.1 - EUROWEB1 - 2012-05-22 01:19:33 - 2012-05-22 00:19:33 - 1000 - Website: OKAY